A Study of Tadalafil for Duchenne Muscular Dystrophy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01865084 |
Recruitment Status :
Terminated
(The study is being terminated for lack of efficacy)
First Posted : May 30, 2013
Results First Posted : March 1, 2017
Last Update Posted : October 9, 2019
|
Sponsor:
Eli Lilly and Company
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | May 24, 2013 | ||||||||||||||||
First Posted Date ICMJE | May 30, 2013 | ||||||||||||||||
Results First Submitted Date ICMJE | September 30, 2016 | ||||||||||||||||
Results First Posted Date ICMJE | March 1, 2017 | ||||||||||||||||
Last Update Posted Date | October 9, 2019 | ||||||||||||||||
Study Start Date ICMJE | September 2013 | ||||||||||||||||
Actual Primary Completion Date | December 2015 (Final data collection date for primary outcome measure) | ||||||||||||||||
Current Primary Outcome Measures ICMJE |
Change From Baseline in Six Minute Walk Distance (6MWD) in Meters [ Time Frame: Baseline, Week 48 ] 6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a "safety chaser" to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.
|
||||||||||||||||
Original Primary Outcome Measures ICMJE |
Change from Baseline in Six Minute Walk Distance (6MWD) in Meters [ Time Frame: Baseline, Week 48 ] | ||||||||||||||||
Change History | |||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||
Original Secondary Outcome Measures ICMJE |
|
||||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||
Descriptive Information | |||||||||||||||||
Brief Title ICMJE | A Study of Tadalafil for Duchenne Muscular Dystrophy | ||||||||||||||||
Official Title ICMJE | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy | ||||||||||||||||
Brief Summary | The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks. | ||||||||||||||||
Detailed Description | Not Provided | ||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||
Study Phase ICMJE | Phase 3 | ||||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||||||||||||||
Condition ICMJE | Muscular Dystrophy, Duchenne | ||||||||||||||||
Intervention ICMJE |
|
||||||||||||||||
Study Arms ICMJE |
|
||||||||||||||||
Publications * |
|
||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||
Recruitment Information | |||||||||||||||||
Recruitment Status ICMJE | Terminated | ||||||||||||||||
Actual Enrollment ICMJE |
331 | ||||||||||||||||
Original Estimated Enrollment ICMJE |
306 | ||||||||||||||||
Actual Study Completion Date ICMJE | March 2016 | ||||||||||||||||
Actual Primary Completion Date | December 2015 (Final data collection date for primary outcome measure) | ||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||||
Ages ICMJE | 7 Years to 14 Years (Child) | ||||||||||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||
Listed Location Countries ICMJE | Argentina, Belgium, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States | ||||||||||||||||
Removed Location Countries | |||||||||||||||||
Administrative Information | |||||||||||||||||
NCT Number ICMJE | NCT01865084 | ||||||||||||||||
Other Study ID Numbers ICMJE | 15122 H6D-MC-LVJJ ( Other Identifier: Eli Lilly and Company ) |
||||||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||||||
U.S. FDA-regulated Product | Not Provided | ||||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||||
Current Responsible Party | Eli Lilly and Company | ||||||||||||||||
Original Responsible Party | Same as current | ||||||||||||||||
Current Study Sponsor ICMJE | Eli Lilly and Company | ||||||||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||||||||
Collaborators ICMJE | Not Provided | ||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||
PRS Account | Eli Lilly and Company | ||||||||||||||||
Verification Date | September 2019 | ||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |